OZ Odyseus

Email

jasekova@ozodyseus.sk

Phone

T: +421903786706

Web

https://www.ozodyseus.sk

Address

Tomášikova 26 Bratislava 82101 Slovakia
About OZ Odyseus

Odyseus, a civic association is a professional harm reduction organisation active in Slovakia since 1997. Odyseus provides services for people who inject drugs, sex workers, young people and people experiencing homelessness. With its activities, Odyseus contributes to social inclusion and the protection of public health. Regarding the viral hepatitis activities – they provide needle and syringe exchange programme and distribution of other health and harm reduction material, low threshold testing for HIV, syphilis, HCV and HBV and linkage to care to those with reactive result. In the period from 1.1.2024 to 31.12.2024, OZ Odyseus carried out 58 rapid tests for HCV. The result was: 16 negative tests and 42 reactive tests. With reactive clients, the workers discussed their options for completing the next process – confirmatory testing, connection to healthcare and future treatment. If they decided that they wanted to start this process, a visit to a specialist in a health facility was arranged. The workers accompanied the clients through the entire process.
Of the 42 clients who tested reactive for HCV, 18 were sent for treatment to a specialist. The remaining clients did not have either an ID card or an insurance card, which are required to make an appointment with a specialist, and 11 of them refused treatment or further process. When we talk about “referral” for treatment, it means that the client has been scheduled to see a specialist. “Linked to healthcare” means that the client has attended an appointment at the clinic and has had contact with medical staff. A total of 52 appointments were scheduled for 21 clients*, but only 38 of them were made (the client showed up). This means that of the 21 clients who were referred to a specialist, 12 were linked to healthcare. Of these 12 clients, 11 have received confirmatory test results, while 1 person is still waiting for their results. Of the 11 clients who have received test results, 3 have tested negative for HCV, while the remaining 8 have tested positive. Of these 8 clients, all have been approved for treatment by their health insurance company. (In Slovakia, HCV treatment must be approved for each patient by the health insurance company. This means that after a positive confirmatory PCR test in a health facility, the doctor must submit an application to the relevant health insurance company on behalf of the patient. The approval process by health insurance companies can take up to 30 days.) None of these clients refused treatment after approval. Three clients successfully completed treatment, while the other 5 are in the process of treatment. In addition, treatment was approved for two persons after reinfection, who also successfully completed treatment.

 

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close